Kenvue Inc. (KVUE)
NYSE · Consumer Defensive · Household & Personal Products
$17.39+1.10%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $33.4B
- P/E (trailing)
- 20.2
- Forward P/E
- 14.0
- Dividend yield
- 4.8%
- 52-week range
- $14.02 – $20.13
- 52-week change
- +6.04%
- EPS (trailing)
- $0.86
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $15.1B (−2.14%)
- Net income
- $1.5B
- Operating margin
- 16.0%
- Diluted EPS
- $0.76
- Free cash flow
- $1.7B
From the company’s annual report on SEC EDGAR.
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.
Headquarters: Summit, United States · 21,780 employees · kenvue.com